Literature DB >> 6981579

Adaptation of human long-term B lymphoblastoid cell lines to chemically defined, serum-free media.

H Muzik, M E Shea, C C Lin, H Jamro, S Cassol, L M Jerry, L Bryant.   

Abstract

Attempts were made to adapt human long-term B lymphoblastoid cell lines to prolonged growth in serum-free, chemically defined media. A newly described medium, which is an enriched modification of Dulbecco's modified Eagle's medium containing additional amino acids and vitamins, was used. The serum is totally replaced by albumin, transferrin, and soybean lipid. The cell lines were all adaptable from RPMI 1640 over a period of time during which the 10% fetal bovine serum (FBS) concentration was reduced and then eliminated in successive steps. After 3 to 6 wk minor alterations in cell shape and adhesion were noted without significant histological changes. Growth characteristics were comparable in the new medium provided a double initial inoculum was used. A panel of cell surface markers, including surface immunoglobulins, Ia antigens, Fc and complement receptors, and T and B erythrocyte rosettes, all showed no altered expression. Molecular genotyping of Ia antigens was carried out by 3-D gel electrophoresis. The antigens showed their full polymorphism without change and were shed into the new culture medium without alteration. Chromosome analysis was performed on Q-banded karyotypes from one of the lines and showed no alteration resulting from the change to serum-free conditions. Thus long-term B lymphoblastoid cell lines can be adapted to prolonged growth in serum-free medium. This will facilitate the assay and isolation of cell products regulating lymphocyte function and the identification and characterization of cell surface molecules free of interference from undefined serum components.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981579     DOI: 10.1007/BF02810074

Source DB:  PubMed          Journal:  In Vitro        ISSN: 0073-5655


  25 in total

1.  A subpopulation of human B lymphocytes that rosette with mouse erythrocytes.

Authors:  I J Forbes; P D Zalewski
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  Enhanced autoradiographic detection of 32P and 125I using intensifying screens and hypersensitized film.

Authors:  R A Laskey; A D Mills
Journal:  FEBS Lett       Date:  1977-10-15       Impact factor: 4.124

4.  Improved medium for clonal growth of human diploid fibroblasts at low concentrations of serum protein.

Authors:  W L McKeehan; K A McKeehan; S L Hammond; R G Ham
Journal:  In Vitro       Date:  1977-07

5.  Growth of a human breast cancer cell line in serum-free hormone-supplemented medium.

Authors:  J C Allegra; M E Lippman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

6.  Defined media and the determination of nutritional and hormonal requirements of mammalian cells in culture.

Authors:  A Rizzino; H Rizzino; G Sato
Journal:  Nutr Rev       Date:  1979-12       Impact factor: 7.110

7.  Tissue localization of two populations of human lymphocytes distinguished by membrane receptors.

Authors:  N P Silveira; N F Mendes; M E Tolnai
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

Review 8.  Methods for growth of cultured cells in serum-free medium.

Authors:  D Barnes; G Sato
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

9.  Isolation of a human B lymphocyte membrane protein with Ia-like properties.

Authors:  A K Sullivan; L M Jerry; R L Ikeman; R J Maccari; H L Thi; C Sylvester
Journal:  Can J Biochem       Date:  1979-01

10.  Comparative cytogenetic studies of normal and leukemic lymphoblastoid cell lines during the course of their establishment.

Authors:  A M Vénuat; C Rosenfeld; M J Testu
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.